SYNERGY™ 48 mm

Long Lesions represent a complex lesion subset that is associated with increased safety related events, reduced efficacy and increased procedure time

 

The 48 mm SYNERGY™ BP Stent addresses long lesion complexity

• Superior deliverability and visibility
• Excellent conformability to vessel anatomy
• Largest on-label overexpansion limits to accommodate proximal to distal tapered vessels
• Preserving side branches with thin struts and 2-connector design
• Biodegradable polymer inhibits delayed arterial healing and neoatherosclerosis

Baseline

Post PCI 

 

Thin strut design to reduce vessel injury and risk of thrombogenicity

 

SYNERGY™
BP Stent

• The Synchrony™ Bioabsorbable PLGA Polymer coating is applied only to the abluminal side of the SYNERGY™ BP Stent to stimulate healthy endothelialization
• SYNERGY™ BP Stent has shown full stent strut coverage as early as 30-days in humans*
• Boston Scientific's Platinum Chromium alloy was designed specifically for coronary stents

 

Bioabsorbable Polymer in Perspective

SYNERGY™ BP Stent offers peace of mind knowing that the polymer is gone shortly after the drug is completely eluted at 3-months*

*Adapted from presentation by Ida Riise Balleby, MD at ACC 2016.

 

SYNERGY™ BP Stent reduced acute inflammation versus BMS and late inflammation versus permanent polymer stents in a preclinical model

 

PtCr Alloy is the foundation of stent performance

Platinum Chromium Alloy

• Platinum has over 2x the density of iron or cobalt
• Platinum provides increased strength when alloyed with stainless steel
• Specifically developed for coronary stents

Key Advantages

• Enhanced visibility
• Exceptional radial strength and conformability
• Minimized recoil

 

Labeled Post-Dilatation Limits

Highest on-label post dilatation limits

^*Adapted from presentations by Juan Granada, MO at TCT2014 (and PCR 2014). Evaluated the PtCr Bare-Metal Stent Preclinical; Diseased Porcine Model.
^tSYNERGY™ Stent System, Promos PREMIER Stent System, Xience Alpine Stent, Resolute Integrity Stent DFU.

 

SYNERGY BP Stent, now available in 48mm

STENT LENGTH (mm)

0 (mm)	8	12	16	20	24	28	32	38	48	Overexpansion Capabilities
2.25	H7493926208220	H7493926212220	H7493926216220	H7493926220220	H7493926224220	H7493926228220	H7493926232220	H7493926238220		3.50
2.50	H749392621N1250	H7493926212250	H7493926216250	H7493926220250	H7493926224250	7493926228250	H7493926232250	H7493926238250	H7493926248250	3.50
2.75	H749392fi200270	H7493926212270	H7493926216270	H7493926220270	H7493926224270	H749392622B270	H7493926232270	H7493926238270	H7493926248270	3.50
3.00	H749392fi208300	H7493926212300	H7493926216300	H7493926220300	H7493926224300	H7493926228300	H7493926232300	H7493926238300	H7493926248300	4.25
3.50	H7493921i208350	H7493926212350	H7493926216350	H7493926220350	H7493926224350	H74939?.6228350	H7493926232350	H7493926238350	H7493926248350	4.25
4.00	H749392fi208400	H7493926212400	H7493926216400	H7493926220400	H7493926224400	H7493926228400	H7493926232400	H7493926238400	H7493926248400	5.75
4.50		H7493926212450	H7493926216450	H7493926220450	H7493926224450	H7493926228450	H7493926232450			5.75
5.00		H7493926212500	H7493926216500	H7493926220500	H7493926224500	H7493926228500	H74939262J2500			5.75

 

Quality Outcomes for Patients

EVOLVE 48 Clinical Trial

2-year results with the SYNERGY 48 mm BP Stent^*:

• 100 patients
• 15 sites across U.S., Europe, and New Zealand
• 100% B2/C lesions
• 27% diabetes mellitus

 

---

Early Healing

Find out how synchronous drug elution and polymer absorption enables early healing.

SYNERGY™ Clinical Overview

Discover the clinical evidence on the SYNERGY™ BP Stent, including multiple short DAPT studies.

Exceptional Deliverability

Learn about the continued advancement in deliverability that SYNERGY™ offers.